Analysts have been eager to weigh in on the Healthcare sector with new ratings on Integra Lifesciences (IART), Savara (SVRA) and Arrowhead Pharmaceuticals (ARWR).
Integra Lifesciences (IART)
In a report released today, Steven Lichtman from Oppenheimer assigned a Buy rating to Integra Lifesciences, with a price target of $60.00. The company’s shares closed last Thursday at $51.18.
According to TipRanks.com, Lichtman is a 1-star analyst with an average return of -3.4% and a 50.4% success rate. Lichtman covers the Healthcare sector, focusing on stocks such as Helius Medical Technologies, Zimmer Biomet Holdings, and Merit Medical Systems.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Integra Lifesciences with a $60.38 average price target, implying a 23.9% upside from current levels. In a report released yesterday, BTIG also maintained a Buy rating on the stock with a $59.00 price target.
See today’s analyst top recommended stocks >>
Savara (SVRA)
In a report released today, Michael Higgins from Ladenburg Thalmann & Co. maintained a Hold rating on Savara, with a price target of $2.50. The company’s shares closed last Thursday at $2.55, close to its 52-week low of $0.69.
According to TipRanks.com, Higgins is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -8.2% and a 30.8% success rate. Higgins covers the Healthcare sector, focusing on stocks such as Eiger Biopharmaceuticals, Zynerba Pharmaceuticals, and Rhythm Pharmaceuticals.
Savara has an analyst consensus of Moderate Buy, with a price target consensus of $5.50.
Arrowhead Pharmaceuticals (ARWR)
Arrowhead Pharmaceuticals received a Buy rating and a $58.00 price target from Oppenheimer analyst Esther Rajavelu today. The company’s shares closed last Thursday at $35.13.
According to TipRanks.com, Rajavelu is a 2-star analyst with an average return of 0.2% and a 41.6% success rate. Rajavelu covers the Healthcare sector, focusing on stocks such as Biohaven Pharmaceutical Holding Co, Teva Pharmaceutical Industries, and Rocket Pharmaceuticals.
Currently, the analyst consensus on Arrowhead Pharmaceuticals is a Moderate Buy with an average price target of $49.80.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
